Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

This solicitation, ARPA-H-SOL-25-122 (THRIVE), seeks proposals for high-impact solutions to challenging health problems, accelerating better health outcomes. Evaluation will focus on potential contribution and relevance to the ARPA-H mission, proposer capabilities and experience, and cost realism. Proposals must articulate clear objectives, current practice limitations, the novelty of their approach, and potential impact, including a detailed R&D timeline and team qualifications. A critical requirement is a good faith representation of intellectual property (IP) ownership or appropriate licensing rights for all IP used in the proposed effort, which will be requested in a full proposal. Proposers must also align their quantitative and qualitative success criteria with the program objectives and associated metrics outlined in Table 1, while demonstrating flexibility and innovation. The government will assume unlimited rights to all IP not explicitly identified as restricted in the proposal.

Notice ID

2117b115a5944724b22c5b231a37989c

Solicitation Number

ARPA-H-SOL-25-122

NAICS Code

541714

Classification Code

AN13